List of works - Dana Horáková

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

scientific article published on 28 February 2019

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients

scientific article published on 16 February 2016

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

scientific article

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

scientific article published on 21 January 2016

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes

scientific article published on 27 January 2014

Clinical correlates of grey matter pathology in multiple sclerosis

scientific article

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

scientific article

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

scientific article published on 6 April 2016

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

scientific article published on 5 December 2014

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

scientific article published on April 2016

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

scientific article published on April 2015

Complement activation in patients with neuromyelitis optica.

scientific article published on 11 July 2014

Contribution of different relapse phenotypes to disability in multiple sclerosis.

scientific article published on 7 April 2016

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

scientific article

Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.

scientific article published on 6 June 2012

Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis

scientific article published on 19 May 2020

Defining reliable disability outcomes in multiple sclerosis.

scientific article published on 10 September 2015

Defining secondary progressive multiple sclerosis

scientific article published on 7 July 2016

Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis

scientific article

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

scientific article

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

scientific article published on 15 June 2020

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

scientific article

Early predictors of non-response to interferon in multiple sclerosis

scientific article published on 16 March 2012

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

scientific article

Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years

scientific article published on 11 April 2013

Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study

scientific article

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

scientific article published on 24 January 2009

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

scientific article published on 31 May 2011

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

scientific article published on 3 November 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

scientific article published on 28 September 2016

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study

scientific article published on 30 April 2014

Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach

scientific article published on 22 November 2016

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

scientific article published on 11 September 2015

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

scientific article published on 2 August 2013

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

scientific article published on 7 March 2012

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

scientific article published on 26 May 2016

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

scientific article published on 17 April 2013

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

scientific article published on April 2017

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

scientific article published on 22 June 2014

Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.

scientific article

MRI correlates of disability progression in patients with CIS over 48 months

scientific article

Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids

scientific article published on 01 October 2004

Multiple sclerosis and the accumulation of iron in the Basal Ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry

scientific article published on 30 January 2010

Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome.

scientific article published on 11 April 2013

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

scientific article published on 09 February 2017

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

scientific article

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

scientific article published on 17 March 2009

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

scientific article

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

scientific article published on 4 May 2016

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

scientific article published on 01 October 2020

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

scientific article

Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)

scientific article published on 06 August 2016

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

scientific article published on 24 November 2016

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

scientific article published on 22 May 2009

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment

scientific article published on 8 October 2014

Reliable measurements of brain atrophy in individual patients with multiple sclerosis.

scientific article

Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study

scientific article published on 19 May 2012

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

scientific article published on 19 January 2016

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

scientific article published on 6 December 2016

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study

scientific article published on 17 June 2014

Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis

scientific article published on 12 April 2012

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

scientific article published on 17 January 2015

Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

scientific article published on 27 April 2017

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

scientific article published on 21 July 2015

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

scientific article published in September 2017

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

scientific article published on 10 February 2017

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

scientific article

List of works by Dana Horáková

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes

Clinical correlates of grey matter pathology in multiple sclerosis

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

Complement activation in patients with neuromyelitis optica.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.

Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis

Defining reliable disability outcomes in multiple sclerosis.

Defining secondary progressive multiple sclerosis

Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

Early predictors of non-response to interferon in multiple sclerosis

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years

Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study

Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.

MRI correlates of disability progression in patients with CIS over 48 months

Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids

Multiple sclerosis and the accumulation of iron in the Basal Ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry

Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome.

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment

Reliable measurements of brain atrophy in individual patients with multiple sclerosis.

Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study

Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study